Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).

被引：0
|
作者：
Goyal, Lipika
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Garmezy, Benjamin
Kobayashi, Ken
Franovic, Aleksandra
Tam, Betty
Voong, Cynthia
机构：
[1] Harvard Med Sch, Mass Gen Canc Ctr, Boston, MA USA
[2] Sarah Cannon Res Inst Florida Canc Specialists, Orlando, FL USA
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA
[4] START Midwest, Grand Rapids, MI USA
[5] PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Kinnate BioPharma Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9601
引用
收藏
页数：1
相关论文
共 11 条
  • [1] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Garmezy, Benjamin
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
  • [3] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
  • [4] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [5] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
    Tyhonas, John S.
    Arnold, Lee D.
    Cox, Jason M.
    Franovic, Aleksandra
    Gardiner, Elisabeth
    Grandinetti, Kathryn
    Kania, Robert
    Kanouni, Toufike
    Lardy, Matthew
    Li, Chun
    Martin, Eric S.
    Miller, Nichol
    Mohan, Adithi
    Murphy, Eric A.
    Perez, Michelle
    Soroceanu, Liliana
    Timple, Noel
    Uryu, Sean
    Womble, Scott
    Kaldor, Stephen W.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
  • [6] A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
    Papadopoulos, K.
    Tolcher, A.
    Kittaneh, M.
    Patniak, A.
    Rasco, D.
    Chambers, G.
    Newth, G.
    Savage, R.
    Hall, T.
    Schwartz, B.
    Kazakin, J.
    LoRusso, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 125
  • [7] A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
    Iyer, Gopa
    Siefker-Radtke, Arlene
    Milowsky, Matthew
    Shore, Neal
    Gao, Xin
    Reimers, Melissa A.
    Hahn, Noah
    Cosman, Rasha
    Matsubara, Nobuaki
    Necchi, Andrea
    Robbrecht, Debbie
    Vinceneux, Armelle
    Grande, Enrique
    Lee, Jae-Lyun
    Zhang, Tian
    Guren, Tormod
    Lauer, Ulrich M.
    Sarfaty, Michal
    Eigl, Bernhard
    Hussain, Syed
    Zhao, Xiang
    Balar, Arjun V.
    Francese, Kaitlyn
    Widau, Ryan
    Garmezy, Benjamin
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [8] A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer
    Tjulandin, Sergei
    Statsenko, Galina
    Artamonova, Elena
    Vladimirova, Liubov Yu
    Besova, Natalia
    Mochalova, Anastasia
    Rykov, Ivan
    Moiseyenko, Vladimir
    Utyashev, Igor A.
    Iugai, Sergei
    Kazey, Vasily
    Raskin, Grigory
    Dragun, Nadezhda
    Reznikov, Dmitry
    Gavrilova, Evgenia
    Tsimafeyeu, Ilya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors
    McKean, Meredith
    Kato, Shumei
    Spira, Alexander
    Xing, Yan
    Xie, Hao
    Buchbinder, Elizabeth
    Kobayashi, Ken
    Williams, Richard
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [10] Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer.
    Tsimafeyeu, Ilya
    Statsenko, Galina
    Mochalova, Anastasia
    Trenina, Natalia
    Kurakin, Vyacheslav
    Besova, Natalia
    Novoselova, Kristina
    Abramova, Natalia
    Obarevich, Ekaterina
    Kashanova, Alina
    Suetina, Margarita
    Moiseyenko, Vladimir
    Byakhov, Mikhail
    Artamonova, Elena
    Vladimirova, Liubov
    Tjulandin, Sergei
    [J]. CANCER RESEARCH, 2021, 81 (13)
12